Bamco Inc. NY Sells 13,975 Shares of argenex SE $ARGX

Bamco Inc. NY cut its stake in shares of argenex SE (NASDAQ:ARGX) by 8.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 153,719 shares of the company’s stock after selling 13,975 shares during the quarter. Bamco Inc. NY owned approximately 0.25% of argenex worth $129,270,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Capital World Investors grew its stake in shares of argenex by 0.4% during the 3rd quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock valued at $1,445,113,000 after acquiring an additional 8,422 shares during the period. M&T Bank Corp grew its stake in shares of argenex by 20,977.7% during the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock valued at $654,772,000 after acquiring an additional 774,916 shares during the period. Wellington Management Group LLP grew its stake in shares of argenex by 80.1% during the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after acquiring an additional 324,653 shares during the period. Morgan Stanley grew its stake in shares of argenex by 19.2% during the 4th quarter. Morgan Stanley now owns 518,852 shares of the company’s stock valued at $436,331,000 after acquiring an additional 83,746 shares during the period. Finally, Sands Capital Management LLC grew its stake in shares of argenex by 2,046.6% during the 4th quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock valued at $300,110,000 after acquiring an additional 340,245 shares during the period. 60.32% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on ARGX shares. Citizens Jmp boosted their price objective on argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a research note on Friday, February 27th. Glj Research upgraded argenex to a “strong-buy” rating in a research note on Friday, April 3rd. Guggenheim boosted their price objective on argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Deutsche Bank Aktiengesellschaft upgraded argenex from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. Finally, Oppenheimer lowered their price target on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a report on Thursday, April 2nd. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,019.50.

argenex Trading Up 1.6%

NASDAQ ARGX opened at $892.26 on Thursday. The stock’s 50 day moving average is $820.36 and its 200 day moving average is $810.81. argenex SE has a 12 month low of $510.05 and a 12 month high of $934.62. The stock has a market cap of $55.49 billion, a PE ratio of 39.73, a P/E/G ratio of 1.34 and a beta of 0.47.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%.The company had revenue of $1.31 billion for the quarter. On average, analysts forecast that argenex SE will post 26.19 EPS for the current fiscal year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.